Articles from Azalea Therapeutics

BERKELEY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today highlighted the publication of foundational research in Nature describing in vivo site-specific genomic integration to reprogram T cells. The research originated as an academic collaboration between the Eyquem laboratory at the University of California, San Francisco and the Doudna laboratory at the University of California, Berkeley. Three of the study's authors – Justin Eyquem, Ph.D., Jenny Hamilton, Ph.D. and Jennifer Doudna, Ph.D. – subsequently co-founded Azalea Therapeutics to advance precise, programmable in vivo cell engineering toward the development of next-generation in vivo CAR T and other cell-based therapies.

BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced new preclinical data demonstrating robust in vivo generation of functional TRAC-CAR T cells using its proprietary Enveloped Delivery Vehicle (EDV) technology. The results will be presented today during the Immune Cell session at the American Society of Gene and Cell Therapy’s (ASGCT’s) Breakthroughs in Targeted In Vivo Gene Editing.

BERKELEY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to advance its proprietary Enveloped Delivery Vehicle (EDV) technology. The company’s mission is to engineer therapeutic cells with precision directly inside the patient, transforming how cell and gene therapies are created and delivered.